News Oligomerix Receives $3.19 Million NIH Commercialization Readiness Pilot Grant for Alzheimer’s Disease Therapy September 15, 2020 By vera This article is sourced from an external publication. Read the original → ← PreviousOligomerix Awarded a $3.19 Million Grant from NIA BioWorldNext →Oligomerix to Present at AAIC 2020 Conference on Small Molecule Inhibitor of Tau Self-Association
